Tumor-treating Fields Do Not Negatively Affect Health-related QoL
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
At the preplanned interim analysis, the study was discontinued for futility.
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
New immunotherapeutic approaches, such as dendritic cell vaccination, may be effective for treating this rare brain cancer, which is associated with dismal survival rates.